Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
SINTX Technologies (NASDAQ: SINT) reported clinical, operational, and leadership milestones positioning the company for commercialization and revenue growth in 2026. Key items include first human implant of the FDA 510(k)-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, a ~$10 million capital raise, and the appointment of Ryan Elmore as President.
The company completed strategic divestitures, acquired SiNAPTIC Surgical, expanded its patent estate into antipathogenic textiles, executed a supply agreement with Evonik, and initiated preclinical studies for sutures, meshes, and wound care.
SINTX Technologies (NASDAQ: SINT) announced a clinical and commercial milestone: the first-in-human surgery using its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System. The device received U.S. FDA 510(k) clearance in October 2025 and was implanted on March 13, 2026, marking SINTX's entry into foot and ankle reconstruction.
The system uses silicon nitride biomaterial, highlighted for osteoconductivity, bacteriostatic surface characteristics, hydrophilicity, and compatibility with X-ray, CT, and MRI imaging. SINTX expects the SINAPTIC system to support a U.S. commercial launch and broader adoption across orthopedic applications.
SINTX Technologies (NASDAQ: SINT) appointed Ryan Elmore as President, effective March 16, 2026, to lead commercialization and channel expansion of silicon nitride biomaterial platforms including SiNERGY™ SiN/PEEK and antipathogenic fibrous materials. The role focuses on scaling revenue via licensing, partnerships, and new product forms (filament, rod, sheet).
The company signaled a strategic shift from product-focused manufacturing toward a broader biomaterials platform targeting implantable and non-implantable medical applications.
SINTX Technologies (NASDAQ: SINT) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on February 4–5, 2026, with its presentation on Wednesday, February 4, 2026 at 12:00 p.m. ET.
The webcast will be available via the company’s investor site. Management will provide updates on operational progress, strategic priorities, its silicon nitride biomaterial platform, recent regulatory milestones, and opportunities in orthopedic, spine, and patient-specific applications.
SINTX Technologies (NASDAQ: SINT) will present at Sidoti & Company’s Year End Virtual Investor Conference held December 10–11, 2025. Management's presentation is scheduled for Wednesday, December 10, 2025 at 3:15 P.M. ET. A live webcast is available and one-on-one meetings can be scheduled by emailing Sintx@kcsa.com. To join the company's email distribution list, email Sintx@kcsa.com with SINT in the subject line.
SINTX Technologies (NASDAQ:SINT) signed a supply agreement with Evonik on Dec 1, 2025 to manufacture its patented silicon nitride–PEEK (SiN/PEEK) compound for AI‑assisted, 3D‑printed patient‑specific implants. Evonik will produce SiN/PEEK to SINTX specifications at commercial scale, enabling immediate manufacture at SINTX’s U.S. facility.
The compound targets antipathogenic surface behavior, osteogenic support, improved imaging vs standard PEEK, and scalable filament supply for humanitarian vertebral body replacement and future regulatory pathways.
SINTX Technologies (NASDAQ: SINT) reported Q3 2025 results and a business update on November 13, 2025, highlighting a U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and first commercial revenue from the private‑labeled OsseoSculpt product. The company said it raised $4.3M in gross proceeds and held $6.25M cash as of September 30, 2025, after executing a sublease expected to save ~$950,000 in lease costs. Q3 financials: revenue $0.2M (vs $0.8M Q3 2024), operating expenses ~$3.4M (down 51% YoY), operating loss $3.4M, net loss $3.5M or $1.19 per diluted share, and adjusted EBITDA loss $2.3M. Near‑term priorities include product launch preparation, KOL engagement, and material extensions into polymer composites.
SINTX Technologies (NASDAQ: SINT) announced the launch and private‑label supply of OsseoSculpt™, a next‑generation biologic designed to complement the company’s FDA 510(k) cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System. Clinical evaluations by multiple design surgeons were completed and SINTX recorded its first commercial revenue in Q3 2025 from early OsseoSculpt orders.
OsseoSculpt features a nanocrystalline HCA surface with biomimetic pore architecture to enhance osteoconduction. The company launched a limited release to select design and early‑adopter sites, with a broader U.S. rollout aligned with wedge availability and surgeon training cycles through Q4 2025–Q1 2026.
SINTX (NASDAQ: SINT) received FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System on October 20, 2025, enabling commercial entry into U.S. reconstructive foot and ankle surgery.
The company plans a U.S. launch in Q1 2026, will leverage U.S.-based manufacturing, and highlights silicon nitride properties including pro-osteogenic effects, bacteriostatic surface behavior (laboratory and animal studies), hydrophilicity, and improved imaging visibility. Industry estimates place the global foot & ankle device market at $4.75–$5.4 billion (2024).
SINTX (NASDAQ: SINT) announced a USPTO Notice of Allowance for a method patent covering its antipathogenic fibrous materials and cited a recently issued U.S. patent No. 12,433,356 (Oct 7, 2025) for the composition. Together, the composition and method patent families expand IP coverage across medical textiles, wound dressings, filtration/PPE, and high-touch clinical surfaces.
The company cites laboratory data showing up to ~99.97% reduction of infectious SARS-CoV-2 in minutes and estimates an addressable market of ~$30B across targeted segments. SINTX plans licensing and co-development deals leveraging both materials and process claims.